Biopharma dealmaking rebounds in Q2 2026: M&A nears $80B and licensing/R&D alliances hit a 5-year record $83B, per DealForma.
It’s always darkest before the biotech dawn, and at no time was that more true than last summer, as biotech was experiencing a crisis of …
This article is available only to Premium subscribers
Upgrade to Premium for unlimited access and Premium exclusives.
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in…
Catalyst is already the fourth biotech acquisition this month, continuing an acceleration of bigger-ticket deals that’s put 2026…
The prospect of patents expiring on lucrative drugs is prompting drugmakers to hunt for the next blockbuster medicines.
With the first half of 2026 officially in the books and another earnings season about to begin, a key question hangs over the…
Pharmaceutical companies are hungry to make deals, and they’re making more than they have in years.
Biotech megarounds rebounded in the first half of 2026, with 40 companies raising $100M+, up from 33 in the same period last year.
